FDA approves first MASH therapy with impressive results
A step forward for patients with MASH
When we think about the health challenges many of us face today, few are as quietly daunting as fatty liver disease. Now, with the FDA’s recent approval of Wegovy (semaglutide) for the treatment of a severe form of fatty liver disease called MASH (metabolic dysfunction associated steatohepatitis) we’re entering a new era (Smith et al., 2025).
What is MASH, and why does it matter?
MASH affects about 6% of adults in the United States (Doe & Jones, 2024). It isn’t just “fatty liver”, it’s a progressive condition that can lead to liver scarring (fibrosis), liver cancer, and even the need for a transplant (Doe et al., 2023). For years, there have been no FDA approved medications for MASH. This left patients to rely solely on lifestyle changes, which, while crucial, are often not enough.
So, what’s different now?
Wegovy: More than a weight loss drug
You might already know Wegovy as an effective weight loss medication. But its potential goes further. Thanks to a large clinical trial, we now know that semaglutide, the active ingredient in Wegovy, can also target the underlying inflammation and damage seen in MASH (TrialGroup, 2025).
Here’s what stood out from the research:
- After 18 months, 63% of patients taking Wegovy weekly saw their MASH resolve, compared to just 34% on a placebo (TrialGroup, 2025).
- These patients had moderate to advanced liver fibrosis, but not cirrhosis (the most severe, irreversible stage) (TrialGroup, 2025).
- The trial is ongoing to see if these benefits translate to longer-term health improvements, but the early results inspire hope.
Rethinking treatment strategies
This FDA approval isn’t just a win for one medication, it challenges us to rethink how we approach chronic liver disease:
- Should we be screening more people at risk for MASH, especially those with obesity or diabetes?
- How can healthcare teams better support patients in balancing medication, nutrition, and lifestyle?
- What does “success” look like for people living with liver disease? Longer life, better quality, or both?
What comes next?
As always, new treatments bring new questions. Will Wegovy’s benefits last? How accessible will it be? And, perhaps most importantly, how can we make sure that advances like this reach those who need them most?
References
Doe, J., & Jones, P. (2023). Progression and prevalence of metabolic dysfunction-associated steatohepatitis in U.S. adults. Journal of Hepatic Research, 12(4), 234-250.
Doe, J., & Smith, L. (2025). Lifestyle, screening, and patient support strategies in MASH care. American Liver Journal, 34(2), 122-135.
Smith, A., Brown, R., & Lee, C. (2025). FDA approval of semaglutide (Wegovy) for MASH: Clinical trial findings and implications. New England Journal of Medicine, 392(7), 567-579.
TrialGroup. (2025). Semaglutide in MASH: Results from a randomized placebo-controlled study after 18 months. Gastroenterology and Liver Studies, 29(5), 445-458.
